Project details

or


Phase Ib study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced ovarian cancer: pharmacokinetics.

Keywords:
chemotherapy pharmacokinetics metformin

Researchers:
dr. M. Jalving
K.E. Broekman
Prof dr A.K.L. Reyners

Type of project:
Stage Wetenschap / Research project

Nature of the research:
Pharmacokinetic analysis of carboplatin/paclitaxel chemotherapy with and without metformin in advanced ovarian cancer. This research project is especially suitable for students with experience in pharmacology.

Fields of study:
pharmacology oncology

Background / introduction
Molecularly targeted agents which inhibit the mTOR pathway and/or
circumvent p53 in the induction of apoptosis are exciting potential targets in ovarian cancer. Metformin is a biguanide, widely used in the treatment of type 2 diabetes mellitus,
that has shown anti-cancer activity in preclinical studies. The main mechanism of metformin’s effect is mTOR pathway inhibition and, in addition, it has been shown to
circumvent p53-induced apoptosis making it an exciting, potentially effective drug in ovarian cancer.
Research question / problem definition
The primary objective of this research project is to document the influence of metformin on the pharmacokinetics of carboplatin/paclitaxel chemotherapy.
Workplan
This research project is part of a phase Ib, single-centre, dose-escalation trial of metformin added to carboplatin/paclitaxel chemotherapy. 12 patients are included for this part of the study. Of all patients blood samples were collected at different time points during chemotherapy cycle 1 (without metformin) and chemotherapy cycle 2 (with metformin). Drug levels of metformin, carboplatin and paclitaxel will be measured in cooperation with the department of pharmacology and the pharmacokinetics of the three drugs will be evaluated.
back to toptop